Skip to main navigation Skip to search Skip to main content

MITHRIDATE, A Multicenter International sTudy comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera

Project Details

Short titleMITHRIDATE, A Multicenter International sTudy comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera
StatusActive
Effective start/end date21/09/18 → 20/09/29

Funding

  • Novartis Pharma A.G.
  • Guys & St Thomas Charity